Endothelium-Dependent, Vasopressin-Induced Contractions in Rabbit Renal Arteries

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 6, 2003, Pages 703-709

  Streefkerk, Jörn O ^a   Pfaffendorf, Martin ^a   Van Zwieten, Pieter A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Endothelium; Rabbit; Renal artery; Vasopressin

Indexed keywords

ARGIPRESSIN; BOSENTAN; CHARYBDOTOXIN; DESMOPRESSIN; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIUM DERIVED RELAXING FACTOR; INDOMETACIN; LIPOXYGENASE INHIBITOR; MECLOFENAMIC ACID; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; RELCOVAPTAN; SR 121463 B; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; INCUBATION TIME; ISOLATED ARTERY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RENAL ARTERY;

ANIMALS; ARGININE VASOPRESSIN; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; NITROARGININE; RABBITS; RENAL ARTERY; VASOCONSTRICTION;

EID: 0344586163     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200312000-00002     Document Type: Article

References (35)

1. 2 receptor-mediated effects. Cardiovasc Res. 2001;51:372-390.
2. Altura BM, Altura BT. Vascular smooth muscle and neurohypophyseal hormones. Fed Proc. 1977;36:1853-1860.
3. 2 receptor. J Clin Invest. 1989;84:418-426.
4. 2 agonist in dogs. J Hypertens Suppl. 1988;6:S673-S674.
5. 2 receptor-mediated vasodilation in healthy humans. J Cardiovasc Pharmacol. 1995;25:387-392.
6. Haslam RJ, Rosson GM, Aggregation of human blood platelets by vasopressin. Am J Physiol. 1972;223:958-967.
7. Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977;1:869-872.
8. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol. 1994;15:321-350.
9. Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263-266.
10. Goldsmith SR, Francis GS, Cowley AW Jr, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385-1390.
11. Bakris G, Bursztyn M, Gavras I, et al. Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997;15:545-550.
12. Cowley AW Jr, Cushman WC, Quillen EW Jr, et al. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension. 1981;3:193-100.
13. Os I, Kjeldsen SE, Skjoto J, et al. Increased plasma vasopressin in low renin essential hypertension. Hypertension. 1986;8:506-513.
14. Garcia-Villalon AL, Garcia JL, Fernandez N, et al. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol. 1996;118:1848-1854.
15. Hayoz D, Weber R, Pechere A, et al. Heterogeneous vascular response to vasopressin: radial artery versus forearm blood flow. J Hypertens. 1997; 15:35-41.
16. 2 receptor defect. J Hypertens. 1995;13:1695-1700.
17. Resta TC, Walker BR. Enhanced renal vasoconstrictor responsiveness to vasopressin after renal denervation. J Cardiovasc Pharmacol. 1999;33: 711-717.
18. 2 vasopressin-receptor-mediated renal vasodilation. J Cardiovasc Pharmacol. 1994;23:331-336.
19. 2 receptors in conscious dogs. Am J Physiol. 1993; 265:R934-R942.
20. 2 receptor stimulation in afferent arterioles. Kidney Int. 1996;49: 722-729.
21. Dora KA, Doyle MP, Duling BR. Elevation of intracellular calcium in smooth muscle causes endothelial cell generation of NO in arterioles. Proc Natl Acad Sci U S A. 1997;94:6529-6534.
22. Dora KA, Hinton JM, Walker SD, et al. An indirect influence of phenylephrine on the release of endothelium-derived vasodilators in rat small mesenteric artery. Br J Pharmacol. 2000;129:381-387.
23. Rudichenko VM, Beierwaltes WH. Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res. 1995;32:100-105.
24. Katusic Z, Krstic MK. Vasopressin causes endothelium-independent contraction of the rat arteries. Pharmacology. 1987;35:264-271.
25. Medina P, Vila JM, Martinez MC, et al. Effects of vasopressin on human renal arteries. Eur J Clin Invest. 1996;26:966-972.
26. Hirata Y, Hayakawa H, Kakoki M, et al. Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney. Hypertension. 1997; 29:58-64.
27. Okamura T, Toda M, Ayajiki K, et al. Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J Vasc Res. 1997;34:464-472.
28. 2-induced vasodilatation in dogs. Am J Physiol. 1994;266:H99-106.
29. Busse R, Edwards G, Feletou M, et al. EDHF: bringing the concepts together. Trends Pharmacol Sci, 2002;23:374-380.
30. Nelson MT, Cheng H, Rubart M, et al. Relaxation of arterial smooth muscle by calcium sparks. Science. 1995;270:633-637.
31. Aldasoro M, Medina P, Vila JM, et al. Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin. J Vasc Surg. 1997;25:696-703.
32. 2-receptor-mediated relaxation of human renal arteries in response to desmopressin. Am J Hypertens. 1999; 12:188-193.
33. Emori T, Hirata Y, Ohta K, et al. Cellular mechanism of endothelin-I release by angiotensin and vasopressin. Hypertension. 1991;18:165-170.
34. Imai T, Hirata Y, Emori T, et al. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19: 753-757.
35. Yu M, Gopalakrishnan V, Wilson TW, et al. Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension. Am J Physiol Heart Circ Physiol. 2001;281:H2511-H2517.